<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35763378</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Antiviral treatment with fluoxetine for rituximab-associated chronic echovirus 13 meningoencephalitis and myofasciitis.</ArticleTitle><Pagination><StartPage>3117</StartPage><EndPage>3123</EndPage><MedlinePgn>3117-3123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15478</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Enterovirus infections pose a serious threat for patients with humoral deficiencies and may be lethal, whilst the efficacy of proposed treatment options such as corticosteroids, intravenous immunoglobulins and fluoxetine remains debated.</AbstractText><AbstractText Label="METHODS">Viral clearance was investigated in a patient with rituximab-induced B-cell depletion and chronic echovirus 13 (E13) meningoencephalitis/myofasciitis in response to intravenous immunoglobulins and fluoxetine using sequential semi-quantitative E13 viral load measurements by real-time reverse transcription polymerase chain reaction. Fluoxetine concentrations in plasma and cerebrospinal fluid were determined by liquid chromatography mass spectrometry.</AbstractText><AbstractText Label="RESULTS">Intravenous immunoglobulins appeared ineffective in this case of E13 infection, whereas virus clearance in cerebrospinal fluid was obtained after 167 days of oral fluoxetine. Since treatment with corticosteroids resulted in a flare of symptoms, rechallenge with viral load measurements was not attempted.</AbstractText><AbstractText Label="CONCLUSION">In this report of a patient with rituximab-associated chronic echovirus 13 meningoencephalitis, viral clearance in response to single treatment options is assessed for the first time. Our observations further support the in vivo efficacy of fluoxetine against enteroviral infections. More research is needed to establish its efficacy in different enterovirus strains.</AbstractText><CopyrightInformation>© 2022 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vermeersch</LastName><ForeName>Gaël</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7367-3060</Identifier><AffiliationInfo><Affiliation>Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laenen</LastName><ForeName>Lies</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9118-8608</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Reference Centre for Enteroviruses, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lens</LastName><ForeName>Géraldine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Elst</LastName><ForeName>Kim C M</ForeName><Initials>KCM</Initials><Identifier Source="ORCID">0000-0002-4061-0722</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar Rudolf</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Hospitals Leuven, and Laboratory of Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jentjens</LastName><ForeName>Sander</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3602-9078</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaerel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Nieuwenhuyse</LastName><ForeName>Tine</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0898-904X</Identifier><AffiliationInfo><Affiliation>Pharmacy Department, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wollants</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeckx</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Department of Laboratory Medicine, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhaert</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Benedicte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJM</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Health Sciences, Division of Infectious Diseases and Immunology, Section of Virology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woei-A-Jin</LastName><ForeName>F J Sherida H</ForeName><Initials>FJSH</Initials><Identifier Source="ORCID">0000-0001-7840-6156</Identifier><AffiliationInfo><Affiliation>Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004457" MajorTopicYN="Y">Echovirus Infections</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008582" MajorTopicYN="Y">Meningitis, Aseptic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008590" MajorTopicYN="Y">Meningoencephalitis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">fluoxetine</Keyword><Keyword MajorTopicYN="N">hypogammaglobulinaemia</Keyword><Keyword MajorTopicYN="N">intravenous immunoglobulins</Keyword><Keyword MajorTopicYN="N">meningoencephalitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35763378</ArticleId><ArticleId IdType="doi">10.1111/ene.15478</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Bauer L, Manganaro R, Zonsics B, et al. Fluoxetine inhibits enterovirus replication by targeting the viral 2C protein in a stereospecific manner. ACS Infecti Dis. 2019;5(9):1609-1623. doi:10.1021/acsinfecdis.9b00179</Citation></Reference><Reference><Citation>Maillet F, Pineton De Chambrun M, Monzani Q, et al. Enteroviral infections in adults treated with rituximab: a new case of chronic meningitis and myofasciitis and literature review. Revue de Medecine Interne. 2020;41(3):200-205. doi:10.1016/j.revmed.2019.12.018</Citation></Reference><Reference><Citation>Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934-944. doi:10.1002/AJH.26209</Citation></Reference><Reference><Citation>Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100-1105. doi:10.1111/bjh.17266</Citation></Reference><Reference><Citation>Wagner JN, Leibetseder A, Troescher A, Panholzer J, von Oertzen TJ. Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review. J Neurol. 2022;269(2):712-724. doi:10.1007/S00415-021-10494-W</Citation></Reference><Reference><Citation>Hurdiss DL, el Kazzi P, Bauer L, et al. Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex. Sci Adv. 2022;8(1):eabj7615. doi:10.1126/SCIADV.ABJ7615</Citation></Reference><Reference><Citation>Gofshteyn J, Cárdenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94-98. doi:10.1016/j.pediatrneurol.2016.06.014</Citation></Reference><Reference><Citation>Kapadia RK, Gill CM, Baca C, et al. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol. 2021;358:577639. doi:10.1016/J.JNEUROIM.2021.577639</Citation></Reference><Reference><Citation>Sham L, Bitnun A, Branson H, et al. Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine. Neurology. 2019;92(19):916-918. doi:10.1212/WNL.0000000000007468</Citation></Reference><Reference><Citation>Committee for Medicinal Products for Human Use (European Medicines Agency). Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2. 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf</Citation></Reference><Reference><Citation>Engelhart DA, Jenkins AJ. Comparison of drug concentrations in postmortem cerebrospinal fluid and blood specimens. J Anal Toxicol. 2007;31(9):581-587. doi:10.1093/jat/31.9.581</Citation></Reference><Reference><Citation>Renshaw PF, Guimaraes AR, Fava M, et al. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 1992;149(11):1592-1594. doi:10.1176/ajp.149.11.1592</Citation></Reference><Reference><Citation>Cheng HY, Huang YC, Yen TY, et al. The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study. BMC Infect Dis. 2014;14(1):417. doi:10.1186/1471-2334-14-417</Citation></Reference><Reference><Citation>Planitzer CB, Farcet MR, Schiff RI, Ochs HD, Kreil TR. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J Med Virol. 2011;83(2):305-310. doi:10.1002/jmv.21980</Citation></Reference><Reference><Citation>Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006;39(3):191-196. doi:10.1080/08916930600622348</Citation></Reference><Reference><Citation>van Dongen JJM, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. doi:10.1038/SJ.LEU.2403202</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>